AC Immune SA

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

UCB SA said in its 22 October announcement about a near-term presentation of Phase IIa results for bepranemab that the company has regained all rights to the tau-targeting antibody from Roche Holding

Takeda has struck a deal with AC Immune for its Phase I/II anti-Abeta immunotherapy ACI-24.060 in Alzheimer’s disease, which could be worth up to $2.1bn. The Japanese big pharma company is paying $

Neuroscience is a key part of Roche ’s growth strategy, and it has just updated investors on how its pipeline could soon yield several breakthrough drugs. The company covered a broad range of candida